Taken together, the ProstaMine results and results from other cancer types suggest that targeted inhibition of GLI1 or the SHH-GLI1 pathway may reduce the aggressiveness of NKX3-1-loss and RB1-loss PCa. The gene discussed is GLI1; the disease is cancer.